CareDx to Report Second Quarter 2024 Financial Results
By:
CareDx, Inc. via
Business Wire
July 16, 2024 at 07:05 AM EDT
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com. About CareDx – The Transplant Company CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240716115420/en/ Contacts
CareDx, Inc.
More NewsView More
Netflix Wins the Streaming Wars: The $82B Warner Bros. Deal ↗
Today 11:02 EST
5 Robotics Stocks Catching Momentum After New Policy Tailwinds ↗
Today 10:47 EST
3 Finance Stocks Leaving Coal in Investors Stockings ↗
Today 10:28 EST
These 3 Little-Known Stocks Are Analyst Favorites ↗
Today 8:48 EST
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|